COMMUNIQUÉS West-GlobeNewswire

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

14/02/2024 - 20:09

Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial [...]

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

14/02/2024 - 19:48

Regional Medical Oncology Center is activated and open to screen patients Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously anticipated Q3/24 is now [...]

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

14/02/2024 - 19:00

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]

Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

14/02/2024 - 18:47

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc [...]

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

14/02/2024 - 18:29

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: [...]

EssilorLuxottica Q4/FY 2023 Results - 2023: another record year for EssilorLuxottica

14/02/2024 - 18:00

Q4/FY 2023 RESULTS 2023: another record year for EssilorLuxottica Group revenue at constant exchange rates 1 +7.1% in Q4 and FY, third consecutive year >7% Nice acceleration in North America in Q4, EMEA keeping the [...]

EssilorLuxottica résultats T4 et annuels 2023 - 2023: nouvelle année record pour EssilorLuxottica

14/02/2024 - 18:00

Résultats T4 et annuels 2023 2023 : nouvelle année record pour EssilorLuxottica Hausse de +7,1 % du chiffre d'affaires du Groupe au T4 et sur l’année à taux de change constants 1 ; troisième année consécutive supérieure [...]

EssilorLuxottica Board of Directors proposes nominees to the new Board

14/02/2024 - 18:00

EssilorLuxottica Board of Directors proposes nominees to the new Board Charenton-le-Pont, France (February 14, 2024 – 6:00pm) – During its meeting today, EssilorLuxottica Board of Directors decided to propose the re- [...]

EssilorLuxottica: Le Conseil d’administration d’EssilorLuxottica propose des candidats pour le nouveau conseil

14/02/2024 - 18:00

Le Conseil d’administration d’EssilorLuxottica propose des candidats pour le nouveau conseil Charenton-le-Pont, France (14 février 2024 – 18h00) – Réuni aujourd'hui, le Conseil d’administration d'EssilorLuxottica a [...]

Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

14/02/2024 - 18:00

Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients in the EU and U.S [...]

Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires

14/02/2024 - 18:00

Une solution innovante de soins bucco-dentaires destinée aux patients prenant des médicaments anticoagulants, qui présentent un risque accru de saignement prolongé au cours et à la suite d'interventions dentaires [...]

ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV

14/02/2024 - 17:48

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 ( Pharmacokinetics and Safety of Double-dose [...]

Genmab Announces Initiation of Share Buy-Back Program

14/02/2024 - 17:41

Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024 COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: [...]

Genmab Publishes 2023 Annual Report

14/02/2024 - 17:02

Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial [...]

Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.

14/02/2024 - 17:00

CHAMPIONSGATE, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- The International Academy of Oral Medicine and Toxicology (IAOMT) urgently highlights a concerning study, titled " Estimated mercury vapor exposure from amalgams [...]

Unity Care Awarded Grant Under "Outdoors for All" Initiative by California Natural Resources Agency and Governor Newsom

14/02/2024 - 17:00

SAN JOSE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unity Care, a nonprofit organization that serves transition-age foster youth, has been selected to receive a grant under the “Outdoors for All” program, an initiative [...]

Statement of Renovaro Inc

14/02/2024 - 16:01

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece: We felt compelled to comment on the shorter Hindenburg’s opinion [...]

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

14/02/2024 - 15:32

Proposed Combination to Focus on Securing Our Nation’s Supply to Critical Materials and Resources MINNEAPOLIS, MN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today [...]

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

14/02/2024 - 15:00

Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production WOBURN, Mass. and LONGMONT, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN [...]